Trial Profile

A Phase I Study of PD-1 Inhibition With TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dostarlimab (Primary) ; Ropidoxuridine
Indications Carcinoma; Endometrial cancer
Focus Adverse reactions

Most Recent Events

21 Aug 2024 Planned End Date changed from 31 Jul 2026 to 18 Dec 2025.
21 Aug 2024 Status changed from recruiting to active, no longer recruiting.
26 Mar 2024 Planned number of patients changed from 12 to 18.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com